Influence of the ABO Blood Group System on Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
31
12
2021
medline:
25
6
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
The ABO blood group system may influence tumorigenesis, but its prognostic value in liver transplantation (LT) for hepatocellular carcinoma (HCC) has never been assessed. All consecutive patients who underwent LT for HCC between 2013 and 2017 at 9 centers were analyzed. Predictors of tumor recurrence were identified using multivariable analysis, while comparison between group A and non-A recipients was performed after propensity score matching. Among 925 LT recipients, 406 were blood group A, 94 group B, 380 group O, and 45 group AB. On multivariable analysis, group A was associated with tumor recurrence (hazard ratio [HR] = 1.574 [95% confidence interval; 95% CI = 1.034-2.394] P = 0.034). After propensity score matching, 1- and 5-y recurrence rates were 7.4% and 20.1% in group A recipients versus 3.3% and 13.2% in non-A recipients (HR = 1.66 [95% CI = 1.12-2.45], P = 0.011). One and 5-y recurrence-free survivals were 85.2% and 66.8% in group A recipients versus 88.5% and 71.3% in non-A recipients (HR = 1.38 [95% CI = 1.01-1.90], P = 0.045). Among recipients within Milan criteria (n = 604), 1- and 5-y recurrence rates were 5.8% and 12.7% in group A recipients versus 3.1% and 12.2% in non-A recipients (HR = 1.197 [95% CI = 0.721-1.987], P = 0.485). Among recipients outside Milan criteria (n = 182), 1- and 5-y recurrence rates were 12.1% and 43.8% in group A recipients versus 3.9% and 15.6% in non-A recipients (HR = 3.175 [95% CI = 1.526-6.608], P = 0.002). ABO blood system influences the oncological outcome of recipients undergoing LT for HCC. Its incorporation in the prognostication model of LT for HCC may allow improving the management of LT candidates.
Sections du résumé
BACKGROUND
The ABO blood group system may influence tumorigenesis, but its prognostic value in liver transplantation (LT) for hepatocellular carcinoma (HCC) has never been assessed.
METHODS
All consecutive patients who underwent LT for HCC between 2013 and 2017 at 9 centers were analyzed. Predictors of tumor recurrence were identified using multivariable analysis, while comparison between group A and non-A recipients was performed after propensity score matching.
RESULTS
Among 925 LT recipients, 406 were blood group A, 94 group B, 380 group O, and 45 group AB. On multivariable analysis, group A was associated with tumor recurrence (hazard ratio [HR] = 1.574 [95% confidence interval; 95% CI = 1.034-2.394] P = 0.034). After propensity score matching, 1- and 5-y recurrence rates were 7.4% and 20.1% in group A recipients versus 3.3% and 13.2% in non-A recipients (HR = 1.66 [95% CI = 1.12-2.45], P = 0.011). One and 5-y recurrence-free survivals were 85.2% and 66.8% in group A recipients versus 88.5% and 71.3% in non-A recipients (HR = 1.38 [95% CI = 1.01-1.90], P = 0.045). Among recipients within Milan criteria (n = 604), 1- and 5-y recurrence rates were 5.8% and 12.7% in group A recipients versus 3.1% and 12.2% in non-A recipients (HR = 1.197 [95% CI = 0.721-1.987], P = 0.485). Among recipients outside Milan criteria (n = 182), 1- and 5-y recurrence rates were 12.1% and 43.8% in group A recipients versus 3.9% and 15.6% in non-A recipients (HR = 3.175 [95% CI = 1.526-6.608], P = 0.002).
CONCLUSIONS
ABO blood system influences the oncological outcome of recipients undergoing LT for HCC. Its incorporation in the prognostication model of LT for HCC may allow improving the management of LT candidates.
Identifiants
pubmed: 34966104
doi: 10.1097/TP.0000000000004004
pii: 00007890-202207000-00019
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1411-1420Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154:128–139.
Puigvehí M, Hashim D, Haber PK, et al. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant. 2020;20:220–230.
Duvoux C, Roudot-Thoraval F, Decaens T, et al.; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.e3; quiz e14.
Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.
Ling Q, Liu J, Zhuo J, et al. Development of models to predict early post-transplant recurrence of hepatocellular carcinoma that also integrate the quality and characteristics of the liver graft: a national registry study in China. Surgery. 2018;164:155–164
Halazun KJ, Tabrizian P, Najjar M, et al. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690–699.
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203–217.
Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. working group report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104:1136–1142.
Cao X, Wen ZS, Sun YJ, et al. Prognostic value of ABO blood group in patients with surgically resected colon cancer. Br J Cancer. 2014;111:174–180.
Zhou J, Yang LC, He ZY, et al. Prognostic impact of ABO blood group on the survival in patients with ovarian cancer. J Cancer. 2015;6:970–975.
Liumbruno GM, Franchini M. Beyond immunohaematology: The role of the ABO blood group in human diseases. Blood Transfus. 2013;11:491–499.
Franchini M, Liumbruno GM, Lippi G. The prognostic value of ABO blood group in cancer patients. Blood Transfus. 2016;14:434–440.
Welsby IJ, Phillips-Bute B, Mathew JP, et al. ABO blood group influences transfusion and survival after cardiac surgery. J Thromb Thrombolysis. 2014;38:402–408.
Oral A, Sahin T. Prognostic role of ABO blood group and Rhesus factor in cirrhotic patients with hepatocellular carcinoma. Sci Rep. 2019;9:19087.
Li Q, Wu T, Ma XA, et al. Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Ther Clin Risk Manag. 2018;14:991–998.
Wu T, Ma XA, Wang GQ, et al. ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Sci Rep. 2017;7:4412.
Barbier L, Cauchy F. “Hors Tour” Liver Grafts: A Step Towards Optimal Donor and Recipient Matching? World J Surg. 2020;44:925–926.
Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65–70.
Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54:343–349.
Bossuyt PM, Reitsma JB, Bruns DE, et al.; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
Durand JK, Willis MS. Karl Landsteiner, MD. Transfusion medicine. Lab Med. 2010;41:53–55
Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021;19:317–326.
Goel R, Bloch EM, Pirenne F, et al.; ISBT COVID-19 Working Group. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. Vox Sang. 2021;116:849–861.
Wolpin BM, Kraft P, Xu M, et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:3140–3149.
Lowe JB. The blood group-specific human glycosyltransferases. Baillieres Clin Haematol. 1993;6:465–492.
Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem. 2007;14:377–386.
Rieckmann P, Michel U, Albrecht M, et al. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol. 1995;60:9–15.
Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw. 2004;15:91–98.